2. Disease Areas
  3. Neurological, Eye or Ear Disease
  4. Visual System Disease

Visual System Disease

Diseases of the visual system encompass a wide range of conditions affecting the eyes, visual pathways, and brain regions involved in vision. Common disorders include refractive errors such as myopia, hyperopia, and astigmatism, as well as cataracts, glaucoma, and age-related macular degeneration (AMD). Diabetic eye disease and amblyopia (lazy eye) are also prevalent. These conditions may arise from infectious agents, systemic diseases like diabetes and hypertension, ocular trauma, or neuro-ophthalmic disorders linked to neurological conditions such as Alzheimer’s disease, multiple sclerosis, and optic neuritis.

 

Visual System Disease (89):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-A0079
    Tetracaine 94-24-6 99.87%
    Tetracaine (Amethocaine) is a sodium channel inhibitor and ryanodine receptor (RyR) inhibitor. Tetracaine blocks sodium conduction across nerve cell membranes, preventing rapid sodium ion influx and depolarization. Tetracaine exhibits biphasic effects on spontaneous sarcoplasmic reticulum Ca2+ release in Ca2+-overloaded ventricular myocytes, and increases sarcoplasmic reticulum Ca2+ load. Tetracaine can be used in research related to eye diseases.
    Tetracaine
  • HY-132596A
    Tivanisiran sodium 1848239-71-3
    Tivanisiran sodium (SYL1001 sodium) is a small interfering RNA (siRNA) targeting TRPV1 . Tivanisiran sodium induces the degradation of TRPV1 mRNA, thereby inhibiting protein synthesis. Tivanisiran sodium alleviates ocular discomfort and pain, and improves ocular hyperemia and tear quality. Tivanisiran sodium is applicable to research related to dry eye disease.
    Tivanisiran sodium
  • HY-129630
    Tetrahydrocortisol 53-02-1 99.91%
    Tetrahydrocortisol is a cortisol metabolite that inhibits dexamethasone-induced formation of cross-linked actin networks. Tetrahydrocortisol can be used in the research of primary open-angle glaucoma, glucocorticoid-induced ocular hypertension, Lewis lung carcinoma, and EMT-6 mouse breast cancer.
    Tetrahydrocortisol
  • HY-163690
    HTRA1-IN-1 3052552-04-9
    HTRA1-IN-1 is a potent and selective high temperature requirement A serine peptid 1 (HTRA1) inhibitor with an IC50 of 13 nM. HTRA1-IN-1 can be used for the research of HTRA1-related diseases, such as age-related macular degeneration (AMD), osteoarthritis, and rheumatoid arthritis.
    HTRA1-IN-1
  • HY-P10227
    Xelafaslatide 2040964-58-5 99.88%
    Xelafaslatide (ONL-1204) is a Fas receptor antagonist. Xelafaslatide blocks the Fas receptor signaling pathway and inhibits downstream apoptosis and inflammatory pathways. Xelafaslatide suppresses neuroinflammation and microglial activation in glaucoma models, protects retinal ganglion cells and prevents axonal degeneration. Xelafaslatide is applicable to relevant research on glaucoma.
    Xelafaslatide
  • HY-P11469
    PG-901 322639-20-3 99.35%
    PG-901 is a full, selective MC5R agonist (EC50 = 0.072 nM for hMC5R). PG-901 is also a full antagonist at the hMC3R and the hMC4R (Kb: 1.0 nM and 0.53 nM, respectively). PG-901 significantly diminishes Cytokines (IL-1α, IL-1β, IL-6). PG-901 increases glucose tolerance, reduces blood glucose, decreases retinal damage.
    PG-901
  • HY-P992151
    Sphingomab
    Sphingomab (LT1002) is a mouse-derived IgG1 κ monoclonal antibody and also an inhibitor targeting S1P, with high affinity for S1P and a Kd value of 0.03 ± 0.002 nM. Sphingomab blocks S1P-mediated IL-8 release in ovarian cancer cells. Sphingomab exhibits anti-angiogenic activity in a mouse model of choroidal neovascularization. Sphingomab reduces peripheral blood lymphocyte counts. Sphingomab can be used in the research of ovarian cancer and age-related macular degeneration.
    Sphingomab
  • HY-185048
    PCB-OAA
    PCB-OAA is a biocompatible multivinyl polycarboxybetaine macromonomer and that exhibits anti-fouling activity. PCB-OAA can form a hydrogel in vitreous cavity and shows an appealing ability to prevent significantly inflammatory response, fibrosis and complications such as raised intraocular pressure, and cataract formation. PCB-OAA can be used for the research of vitreous substitution.
    PCB-OAA
  • HY-NP0147
    Wheat Germ Agglutinin (Fluorescein)
    Wheat Germ Agglutinin (WGA) Fluorescein is a classic fluorescent label that specifically binds to sugar residues such as N-acetylglucosamine, N-acetylneuraminic acid and sialic acid. Wheat Germ Agglutinin Fluorescein performs regionally differential fluorescent staining of the ocular surface epithelial glycocalyx to assess its integrity, and causes no damage to the eye at safe concentrations. Wheat Germ Agglutinin Fluorescein is also used for staining structures including red blood cells, cultured cells, bacteria and pine wood nematodes, and facilitates the isolation of wheat-associated plant-growth-promoting rhizobacterial strains. Wheat Germ Agglutinin Fluorescein can be applied to the detection of ocular glycocalyx integrity and the research of related diseases such as pine wilt disease.
    Wheat Germ Agglutinin (Fluorescein)
  • HY-107661
    Arundic Acid 185517-21-9 98.0%
    Arundic Acid is an orally effective astrocyte function modulator and neuroprotective agent. Arundic Acid increases the expression and function of the astrocytic glutamate transporter EAAT1 by activating the ERK, Akt and NF-κB pathways. Arundic Acid attenuates retinal ganglion cell death in a normal-tension glaucoma model. Arundic Acid exerts neuroprotective effects in a mouse model of Parkinson's disease. Arundic Acid is a S100β protein synthesis inhibitor that prevents neurological deficits and brain tissue damage after intracerebral hemorrhage in rats. Arundic Acid downregulates neuroinflammation and astrocytic dysfunction after status epilepticus in immature rats. Arundic Acid is applicable to research related to Parkinson's disease, cerebral ischemia, glaucoma, intracerebral hemorrhage and epilepsy.
    Arundic Acid
  • HY-19518
    Latanoprostene bunod 860005-21-6 99.75%
    Latanoprostene bunod (NCX116; LBN) is a nitric oxide-releasing prostaglandin F2α analog. Latanoprostene bunod is a prodrug that, upon instillation into the eye, is hydrolyzed by corneal esterases into two active metabolites: Latanoprost (HY-B0577) and NO. Latanoprost activates the prostaglandin FP receptor to increase the outflow of aqueous humor through the uveoscleral pathway. NO increases aqueous humor drainage through the trabecular meshwork pathway, achieving synergistic enhancement targeting the dual pathways of aqueous humor outflow. Latanoprostene bunod can be used in research related to open-angle glaucoma and ocular hypertension.
    Latanoprostene bunod
  • HY-B0298
    Clemastine 15686-51-8 99.26%
    Clemastine (HS-592; Meclastine) is an orally active, blood-brain barrier-permeable H1 histamine receptor (H1 histamine receptor) antagonist with potent antiallergic effects. Clemastine also antagonizes muscarinic acetylcholine receptors (mAChR), particularly the M1 and M4 subtypes. In addition to antihistamine effects, Clemastine exhibits multiple pharmacological activities, especially in promoting central nervous system remyelination, activating autophagy and pyroptosis, exerting anti-apoptotic and neuroprotective effects, and suppressing inflammation.
    Clemastine
  • HY-B1076
    Medrysone 2668-66-8 99.79%
    Medrysone (HMS; 6α-Methyl-11β-hydroxyprogesterone) is a STAT6 modulator and M2 macrophage polarization inducer. Medrysone enhances IL-4-triggered STAT6 activation, upregulates the expression of M2 markers, and promotes the secretion of VEGF and CCL2. Medrysone also enhances the pro-migratory activity of M2-like macrophages toward endothelial cells. By regulating macrophage polarization and related repair pathways, Medrysone significantly promotes corneal wound repair in a rat mechanical injury model. Medrysone can be used for research related to corneal injury.
    Medrysone
  • HY-P3226
    JB-1 147819-32-7 99.63%
    JB-1, an IGF-I analog, is a selective IGF-I receptor inhibitor that does not interact with IGF-II. JB-1 competes with IGF-I for binding to IGF-1R and blocks receptor autophosphorylation. JB-1 increases the level of sVEGFR-1. JB-1 normalizes retinal abnormalities, including reducing retinal neovascularization. JB-1 is applicable to studies related to oxygen-induced retinopathy.
    JB-1
  • HY-145628
    CM398 1121931-70-1 99.85%
    CM398 is a highly selective, orally active Sigma-2 receptor ligand with a Ki value of 0.43 nM. CM398 ameliorates age-related macular degeneration. CM398 exerts analgesic effects on visceral pain, inflammatory pain and neuropathic pain. CM398 can be used in research related to age-related macular degeneration, neuropathic pain and inflammatory pain.
    CM398
  • HY-B0633D
    Hyaluronic acid sodium (MW 200-1560) 9067-32-7 99.41%
    Hyaluronic acid sodium (MW 200-1560) is a biopolymer composed of repeating disaccharide units, with a molecular weight of 200-1560. Hyaluronic acid sodium is a major component of the extracellular matrix (ECM). It is synthesized on the plasma membrane. Hyaluronic acid sodium exerts its effects by binding to receptors CD44 and RHAMM. Hyaluronic acid sodium activates PI3K-Akt signaling. Hyaluronic acid sodium also enhances cell invasion and angiogenesis by promoting or stimulating the binding of proteolytic MMP-9 to the cell surface. Elevated hyaluronic acid levels are associated with tumor cell growth, adhesion, migration, invasion, and angiogenesis in digestive system cancers. Hyaluronic acid sodium is involved in tissue remodeling and rapid cell proliferation in several physiological processes, including embryonic morphogenesis and wound healing. Hyaluronic acid sodium can be used as a regulator of cancer-associated lymphangiogenesis. Hyaluronic acid sodium can be used as a drug delivery carrier for sodium butyrate, enhancing its anti-proliferative activity against breast cancer cell lines. Hyaluronic acid sodium can lubricate the corneal endothelium. Hyaluronic acid sodium can improve tissue hydration and enhance the resistance of cells to mechanical damage. Hyaluronic acid sodium has been conjugated with antibodies to ensure that the active compound continues to exert its effects at the site of inflammation. Hyaluronic acid sodium can be used in research in the fields of osteoarthritis, ophthalmology, cosmetic dermatology, oncology, and liver diseases.
    Hyaluronic acid sodium (MW 200-1560)
  • HY-P10086
    TREM-1 inhibitory peptide GF9 1289375-12-7 99.41%
    TREM-1 inhibitory peptide GF9 (Human TREM-1 (213-221)) is a TREM-1 inhibitor. TREM-1 inhibitory peptide GF9 blocks the TREM-1 signaling pathway via a ligand-independent mechanism, spontaneously inserts into the cell membrane to dissociate TREM-1 from DAP-12, and functions through the Signaling Chain Homooligomerization (SCHOOL) model. TREM-1 inhibitory peptide GF9 reduces the levels of TNFα, IL-1β, IL-6, and M-CSF. TREM-1 inhibitory peptide GF9 inhibits tumor growth, prolongs the survival of mice with pancreatic cancer models, ameliorates collagen-induced arthritis, and exerts protective effects on bone and cartilage simultaneously. TREM-1 inhibitory peptide GF9 can be used in research related to arthritis, pancreatic cancer, retinopathy, alcoholic liver disease, and liver cancer.
    TREM-1 inhibitory peptide GF9
  • HY-P990084
    Veligrotug 2728655-31-8 99.25%
    Veligrotug (AVE1642) is a selective, fully human IGF-1R antagonist antibody with a Kd value of 0.55 nM for hIGF-1R. Veligrotug blocks the phosphorylation of downstream AKT. Veligrotug is applicable to research related to thyroid eye disease.
    Veligrotug
  • HY-P991886
    ANX-M1 (Human IgG1) 99.0%
    ANX-M1 is a blood-brain barrier-permeable anti-C1q antibody. ANX-M1 can slow down the progression of retinal degeneration following photo-oxidative damage. ANX-M1 has been incorporated into nanocarriers to evaluate its brain delivery efficacy in a mouse model of Alzheimer's disease. ANX-M1 is applicable for research on age-related macular degeneration and Alzheimer's disease [1].
    ANX-M1 (Human IgG1)
  • HY-151231
    6-Hydroxyluteolin 18003-33-3 98.15%
    6-Hydroxyluteolin (Compound 17) is a flavonoid derivative and also an inhibitor of Aldose reductase, with an experimental -log IC50 value of 6.690. 6-Hydroxyluteolin can be isolated from the leaves of multiple plant families, including Plantaginaceae, Globulariaceae and Labiatae. 6-Hydroxyluteolin serves as a phylogenetic marker for higher plants. 6-Hydroxyluteolin can be used in the research of diabetic cataract.
    6-Hydroxyluteolin